VolitionRx Signs LOI with Missionpharma to Develop Lateral Flow Technology for NETosis Testing
VolitionRx (NYSE: VNRX) has entered into a non-binding Letter of Intent (LOI) with Danish healthcare distributor Missionpharma A/S. The collaboration aims to develop and launch Volition's prototype Lateral Flow Technology (LFT) for detecting NETosis, which serves as an early indicator of hyper-inflammation in conditions like sepsis. The partnership seeks to transition Volition's diagnostic capabilities from centralized laboratories to decentralized, finger-prick testing environments. This shift is intended to expand the company's total addressable market by providing low-cost diagnostic tools to resource-constrained regions and humanitarian settings. Initial clinical focus will target neonatal sepsis, a major cause of infant mortality in low- and middle-income countries (LMICs). Missionpharma intends to assist with manufacturing, clinical studies, and global distribution through its established networks, including United Nations agencies.
Topics: Biotechnology Global Health Letter of Intent Medical Technology Product Development